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Background
The heart responds to maladaptive pro-hypertrophic sti-
muli by stimulating intrinsic signals that contrast and
dampen the onset and development of hypertrophy. Cyclic
guanosine monophosphate (cGMP) and its downstream
effector cGMP kinase I (cGKI) have been suggested to be
an important anti-hypertrophic signalling pathway (1).
Intracellular levels of cGMP can be raised by the action of
nitric oxide (NO) and natriuretic peptides (ANP, BNP), or
by inhibiting cGMP-degrading phosphodiesterases (PDE).
Results
A growing body of evidence suggests that the PDE5 spe-
cific inhibitor Sildenafil (Sil) prevents and reverses hyper-
trophy and chamber remodelling in the heart of mice
subjected to thoracic aorta constriction (TAC) by elevat-
ing cGMP levels and cGKI activation (1). In contrast,
using a mouse model that lacks cGKI expression in CM
(2), we recently showed that the absence of this kinase
does not alter the onset of hypertrophy induced by TAC
or isoproterenol infusion (2).
Sil is believed to increase cardiac cGMP levels, although
it is unclear, if its target (PDE5) is expressed in CM (2). Sil
may act on other PDEs, such as PDE1C which is abundant
in CMs. It is also unclear if Sil effects are mediated by
other cardiac cell types, in particular by cardiofibroblast.
Conclusion
To answer these questions, we are currently investigating
whether Sil is able to prevent hormone induced cardiac
hypertrophy in the absence of cGKI in CM. Preliminary
results on bRes mice show that even in the case of
chronic AngII infusion, lack of cGKI In CM does not
alter the Induction of hypertrophic response, at least in
the initial phase (7days of AngII infusion at 2mg/kg/day).
Interestingly, bRes mice showed impaired cardiac func-
tion, as indicated by decreased Fractional Shortening. Sil
was able to partially block the onset of cardiac hypertro-
phy in WT animals, but not in bRes mice, indicating a
requirement of cGKI in this process. In particular, Sil
was able to block the transcription of pro-fibrotic genes
such as TGFb, CTGF, Collagen I and Fibronectin.
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